Plain-English translation of NCT07069725 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a medication called in people with advanced liver fibrosis (severe liver scarring). Researchers will use a special type of imaging called PET scans to see how the medication affects your liver and whether it can help reduce scarring. The goal is to understand whether this treatment works and is safe.
Liver scarring (fibrosis) can progress to cirrhosis, which seriously damages liver function and is difficult to treat. This medication may help slow or reduce liver scarring by targeting specific cells involved in the scarring process, but this needs to be tested in people for the first time.
You likely qualify if…
You likely don't qualify if…
The trial involves two main parts. In Part A, you will have blood tests and one PET imaging scan at a screening visit. If you're selected to continue to Part B, you will return for additional blood tests and up to two more PET scans over several weeks, and you will take doses of the medication during this time. Each visit lasts a few hours, and you'll receive a follow-up phone call about a week after your last scan to check how you're doing.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Sweden
Phase
Safety & dosing
Sponsor
AstraZeneca
Collaborators
CTC Clinical Trial Consultants AB, Karolinska Institutet
Enrollment target
~12 participants
Started
May 2025
Primary completion
July 2026
Age range
20 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
AstraZeneca
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.